The prioritisation board, made up of senior members of NICE, drives our decision-making and maintains oversight of our guidance portfolio. It ensures the topics we select reflect national priorities ...

We estimate the NHS could potentially save £millions annually by greater use of the generic version of abiraterone rather than using enzalutamide and apalutamide, the other treatments we recommend at ...

The pipeline of potential treatments is encouraging. Several medicines are in development. Others including GLP-1 agonists like semaglutide (currently used for obesity treatment) are being repurposed ...

HEMA was convened to be an independent voice guiding best practices in international health technology assessment (HTA). It aims to critically examine and assess new methods, and is a collaboration ...

Evidence-based recommendations on betula verrucosa (Itulazax 12 SQ Bet) for treating moderate to severe allergic rhinitis or conjunctivitis caused by pollen from trees in the birch allergy group in ...

There is a simple discount patient access scheme for dostarlimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact [email protected] ...

There is a simple discount patient access scheme for efanesoctocog alfa. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults. Next review: More evidence on elranatamab is being ...

NICE is unable to make a recommendation about the use in the NHS of enzalutamide (Xtandi) for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy. This is because ...

NICE is unable to make a recommendation about the use in the NHS of baricitinib (Olumiant) for treating juvenile idiopathic arthritis in people 2 years and over. This is because Eli Lilly did not ...

NICE is unable to make a recommendation on zanubrutinib (Brukinsa) with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma in adults after 2 or more treatments. This is ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...